当前位置： SCI文献检索 > Clinical Lung Cancer期刊下所有文献 > Nine-year Experience: Prophylactic Cranial Irradiation in Extensive Disease Small-cell Lung Cancer.

Nine-year Experience: Prophylactic Cranial Irradiation in Extensive Disease Small-cell Lung Cancer.

Abstract：

BACKGROUND:In 2007, the European Organization for Research and Treatment of Cancer (EORTC) study (ClinicalTrials.gov identifier, NCT00016211) demonstrated a beneficial effect on overall survival (OS) with the use of prophylactic cranial irradiation (PCI) for extensive disease (ED) small-cell lung cancer (SCLC). Nevertheless, debate is ongoing regarding the role of PCI, because the patients in that trial did not undergo magnetic resonance imaging (MRI) of the brain before treatment. Also, a recent Japanese randomized trial showed a detrimental effect of PCI on OS in patients with negative pretreatment brain MRI findings. MATERIALS AND METHODS:We examined the medical records of 136 patients with ED SCLC who had initially responded to chemotherapy and undergone PCI from 2007 to 2015. The outcomes, radiation toxicity, neurologic progression-free survival, and OS after PCI were analyzed. Survival and correlations were calculated using log-rank and univariate Cox proportional hazard ratio analyses. RESULTS:The median OS and the median neurologic progression-free survival after PCI was 12 and 19 months, respectively. No significant survival difference was seen for patients who had undergone MRI before PCI compared with patients who had undergone contrast-enhanced computed tomography (P = .20). Univariate analysis for OS did not show a statistically significant effect for known cofactors. CONCLUSION:In the present cohort, PCI was associated with improved survival compared with the PCI arm of the EORTC trial, with a nearly doubled median OS period. Also, the median OS was prolonged by 2 months compared with the irradiation arm of the Japanese trial.

journal_name

Clin Lung Cancer

journal_title

Clinical lung cancer

authors

Bernhardt D,Adeberg S,Bozorgmehr F,Opfermann N,Hoerner-Rieber J,Repka MC,Kappes J,Thomas M,Bischoff H,Herth F,Heußel CP,Debus J,Steins M,Rieken S

doi

10.1016/j.cllc.2016.11.012

subject

Has Abstract

pub_date

2017-07-01 00:00:00

pages

e267-e271

issue

4

eissn

1525-7304

issn

1938-0690

pii

S1525-7304(16)30366-7

journal_volume

18

pub_type

杂志文章

相关文献

Clinical Lung Cancer文献大全
  • Importance of quality of life in patients with non-small-cell lung cancer.

    abstract：:The therapeutic options for patients with advanced non-small-cell lung cancer (NSCLC) are palliative. Therefore, the quality of life in oncology is considered as an endpoint in clinical trials, and several scales have been accepted for its measurement in parallel with other clinical determinations. However, its use in...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CLC.2009.n.010

    authors： Camps C,del Pozo N,Blasco A,Blasco P,Sirera R

    更新日期：2009-03-01 00:00:00

  • Results from a single institution phase II trial of concurrent docetaxel/carboplatin/radiotherapy followed by surgical resection and consolidation docetaxel/carboplatin in stage III non-small-cell lung cancer.

    abstract：BACKGROUND:The optimal treatment of locally advanced non-small-cell lung cancer (NSCLC) remains controversial. We hypothesized that using a trimodality approach in selected patients with stage IIIA/IIIB disease would be both feasible and efficacious with reasonable toxicity. PATIENTS/METHODS:We enrolled 13 patients wi...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2011.06.003

    authors： Das M,Donington JS,Murphy J,Kozak M,Eclov N,Whyte RI,Hoang CD,Zhou L,Le QT,Loo BW,Wakelee H

    更新日期：2011-09-01 00:00:00

  • Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.

    abstract：BACKGROUND:Afatinib is approved in the US, Europe, and several other regions for first-line treatment for epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:Treatment-naive patients with advanced EGFRm+ NSCLC were randomized to afatinib (40 mg/d) versus...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.cllc.2018.03.009

    authors： Wu YL,Sequist LV,Tan EH,Geater SL,Orlov S,Zhang L,Lee KH,Tsai CM,Kato T,Barrios CH,Schuler M,Hirsh V,Yamamoto N,O'Byrne K,Boyer M,Mok T,Peil B,Märten A,Chih-Hsin Yang J,Paz-Ares L,Park K

    更新日期：2018-07-01 00:00:00

  • Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.

    abstract：BACKGROUND:Gastric acid-suppressing medications (AS), namely, proton pump inhibitors and histamine-2 receptor antagonists, increase gastric pH, which may reduce the absorption of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors-erlotinib and gefitinib. PATIENTS AND METHODS:From 2008 to 2011, 130 ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2016.01.006

    authors： Zenke Y,Yoh K,Matsumoto S,Umemura S,Niho S,Ohmatsu H,Goto K,Ohe Y

    更新日期：2016-09-01 00:00:00

  • Phase I and II trials of vinorelbine with carboplatin for patients 75 years of age or older with previously untreated non-small-cell lung cancer.

    abstract：BACKGROUND:The safety and efficacy of platinum-based combination chemotherapy for elderly patients with advanced non-small-cell lung cancer (NSCLC) remains unclear. We conducted phase I and phase II trials of a combination of vinorelbine and carboplatin for patients ≥75 years of age and with advanced NSCLC. PATIENTS A...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2011.11.007

    authors： Takatani H,Nakamura Y,Nagashima S,Soda H,Kinoshita A,Fukuda M,Fukuda M,Soejima Y,Kasai T,Nakatomi K,Iida T,Oka M,Tsukamoto K,Kohno S

    更新日期：2012-09-01 00:00:00

  • ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.

    abstract：INTRODUCTION:Platinum-based chemotherapy is besides the standard antifolate therapy with pemetrexed, the cornerstone for treatment of patients with malignant pleural mesothelioma (MPM), and its efficacy depends on several DNA repair enzymes. Therefore, these enzymes could be biomarkers for "tailoring" chemotherapy. Thi...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2013.04.013

    authors： Ting S,Mairinger FD,Hager T,Welter S,Eberhardt WE,Wohlschlaeger J,Schmid KW,Christoph DC

    更新日期：2013-09-01 00:00:00

  • High N-terminal pro-B-type natriuretic peptide: a biomarker of lung cancer?

    abstract：BACKGROUND:The level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) is affected by many known factors. Our study aimed to evaluate whether other factors, in particular lung cancer, could be responsible for an increase in NT-proBNP levels in a population with no known risk factors for elevated NT-proBNP. PATI...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/CLC.2010.n.043

    authors： Aujollet N,Meyer M,Cailliod R,Combier F,Coignet Y,Campard S,Facy O,Bernard A,Girard C

    更新日期：2010-09-01 00:00:00

  • CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status.

    abstract：INTRODUCTION:The aim of the study was to investigate the efficacy and tolerability of panitumumab, a fully human antiepidermal growth factor receptor monoclonal antibody, in combination with pemetrexed/cisplatin in patients with stage IIIB to IV primary nonsquamous non-small-cell lung cancer and wild type V-Ki-ras2 Kir...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.cllc.2015.05.009

    authors： Schuette W,Behringer D,Stoehlmacher J,Kollmeier J,Schmager S,Fischer von Weikersthal L,Schumann C,Buchmann J

    更新日期：2015-11-01 00:00:00

  • Expression levels of protein kinase C-alpha in non-small-cell lung cancer.

    abstract：:Current treatments of non-small-cell lung cancer (NSCLC) are inadequate and new therapies are being developed that target specific cellular signaling proteins associated with tumor growth. One potential target is protein kinase C (PKC)-alpha, a signaling molecule with an important role in cell regulation and prolifera...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/clc.2004.n.032

    authors： Lahn M,Su C,Li S,Chedid M,Hanna KR,Graff JR,Sandusky GE,Ma D,Niyikiza C,Sundell KL,John WJ,Giordano TJ,Beer DG,Paterson BM,Su EW,Bumol TF

    更新日期：2004-11-01 00:00:00

  • Phase II study of sequential treatment of advanced non-small-cell lung cancer: three cycles of high-dose epirubicin plus cisplatin followed by weekly vinorelbine.

    abstract：:Previous phase I, II, and III studies on high-dose epirubicin (HDEPI), alone or in combination with cisplatin (CP), indicate an interesting activity of this drug in the treatment of non-small-cell lung cancer (NSCLC). However, the toxicological profile of HDEPI limits its prolonged use. In our experience, vinorelbine ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/clc.2001.n.017

    authors： Guaraldi M,Marino A,Pannuti F,Farabegoli G,Martoni A

    更新日期：2001-08-01 00:00:00

  • Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.

    abstract：INTRODUCTION:The programmed death 1 antibodies (PD-1 Ab) nivolumab and pembrolizumab improve overall survival (OS) in advanced non-small-cell lung cancer (NSCLC). We evaluated the correlation between immune-related adverse events (irAE) and treatment interruption due to irAE on clinical efficacy of PD-1 Ab in advanced ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.cllc.2018.09.005

    authors： Ksienski D,Wai ES,Croteau N,Fiorino L,Brooks E,Poonja Z,Fenton D,Geller G,Glick D,Lesperance M

    更新日期：2019-01-01 00:00:00

  • Diagnosis and predictive molecular analysis of non-small-cell lung cancer in the Africa-Middle East region: challenges and strategies for improvement.

    abstract：:The identification of tumor biomarkers provides information on the prognosis and guides the implementation of appropriate treatment in patients with many different cancer types. In non-small cell lung cancer (NSCLC), targeted treatment plans based on biomarker identification have already been used in the clinic. Howev...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.cllc.2014.06.005

    authors： Slavik T,Asselah F,Fakhruddin N,El Khodary A,Torjman F,Anis E,Quinn M,Khankan A,Kerr KM

    更新日期：2014-11-01 00:00:00

  • Complications of ablative therapies in lung cancer.

    abstract：:Two cases of complications secondary to the use of microwave ablation (MWA) in non-small-cell lung cancer (NSCLC) are discussed herein. The first case involves a 62-year-old man with stage IB NSCLC who declined surgery and pursued MWA. Within 7 months, he had residual disease at the MWA treatment site, and surgery was...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/CLC.2008.n.019

    authors： Padda S,Kothary N,Donington J,Cannon W,Loo BW Jr,Kee S,Wakelee H

    更新日期：2008-03-01 00:00:00

  • Antisense oligonucleotides in the treatment of non-small-cell lung cancer.

    abstract：:Antisense oligonucleotides (ASONs) are one of the new classes of molecularly targeted agents that have transitioned from the laboratory into clinical trials. Rational drug design has resulted in agents directed against a number of important cellular targets, including the mRNA of bcl-2, protein kinase (PK) C-alpha, PK...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/clc.2003.s.007

    authors： Davies AM,Gandara DR,Lara PN Jr,Mack PC,Lau DH,Gumerlock PH

    更新日期：2003-01-01 00:00:00

  • Role of computed tomography fluoroscopy-guided cutting needle biopsy of lung lesions after transbronchial examination resulting in negative diagnosis.

    abstract：INTRODUCTION:Computed tomography (CT)-guided lung biopsy is occasionally used for the lesions that were diagnosed as nonmalignant by transbronchial examination despite the fact that other clinical data suggested those as malignant. The purpose of this study is to evaluate the outcomes of CT fluoroscopy-guided cutting n...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/CLC.2011.n.007

    authors： Matsui Y,Hiraki T,Mimura H,Gobara H,Inoue D,Iishi T,Toyooka S,Kanazawa S

    更新日期：2011-01-01 00:00:00

  • Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer.

    abstract：BACKGROUND:This study assesses the predictive and prognostic roles of serum soluble intercellular adhesion molecule-1 (sICAM-1) and vascular endothelial growth factor (VEGF) during chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:Changes in serum levels of sICAM-1 and VEG...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2011.03.009

    authors： Qian Q,Zhan P,Yu L,Shi Y,Cheng J,Wei S,Wang Q,Song Y

    更新日期：2011-03-01 00:00:00

  • Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer.

    abstract：BACKGROUND:Little is known about the difference between black and non-black patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), particularly regarding survival. We thus characterized the EGFR expression profile, clinical characteristics, and survival outcome in these patien...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2019.07.003

    authors： Cheng H,Hosgood HD,Deng L,Ye K,Su C,Sharma J,Yang Y,Halmos B,Perez-Soler R

    更新日期：2020-03-01 00:00:00

  • Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer.

    abstract：BACKGROUND:We evaluated the tolerability and efficacy of nimotuzumab, a humanized IgG1 monoclonal anti-epidermal growth factor receptor antibody, with concurrent chemoradiotherapy in patients with unresectable locally advanced non-small-cell lung cancer. PATIENTS AND METHODS:In this multicenter, single-arm, open-label...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2020.12.012

    authors： Yamamoto N,Harada H,Okamoto I,Masuda N,Hayakawa K,Satouchi M,Soejima T,Nishio M,Kozuka T,Takeda K,Tanaka M,Seto T,Sasaki T,Tsubouchi H,Kakurai Y,Nishimura Y,Nakagawa K

    更新日期：2020-12-26 00:00:00

  • Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy.

    abstract：INTRODUCTION:In the phase III LUX-Lung 8 trial, afatinib significantly improved progression-free survival (PFS) and overall survival (OS) versus erlotinib in patients with squamous cell carcinoma (SCC) of the lung progressing during or after platinum-based chemotherapy. Patient-reported outcomes (PROs) and health-relat...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.cllc.2017.06.002

    authors： Felip E,Hirsh V,Popat S,Cobo M,Fülöp A,Dayen C,Trigo JM,Gregg R,Waller CF,Soria JC,Goss GD,Gordon J,Wang B,Palmer M,Ehrnrooth E,Gadgeel SM

    更新日期：2018-01-01 00:00:00

  • Clinical significance of downstaging in patients with limited-disease small-cell lung cancer.

    abstract：BACKGROUND:We investigated the effect of downstaging on OS in LD-SCLC patients treated with first-line treatment. PATIENTS AND METHODS:We retrospectively reviewed 210 LD-SCLC patients who were treated with first-line treatment at Seoul National University Hospital between April 1999 and November 2012. Compared with in...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2013.09.003

    authors： Go SI,Keam B,Kim TM,Lee SH,Kim DW,Kim HJ,Wu HG,Chung DH,Heo DS

    更新日期：2014-03-01 00:00:00

  • Cancer treatments: can we find treasures at the bottom of the sea?

    abstract：:Because of the poor results observed after platinum-based first-line chemotherapy, research on new strategies for second-line treatment of advanced non-small-cell lung cancer (NSCLC) is warranted. Current research focuses on the development of new agents and the assessment of a combination of therapies, especially tho...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CLC.2009.n.041

    authors： Provencio M,Sánchez A,Gasent J,Gómez P,Rosell R

    更新日期：2009-07-01 00:00:00

  • Clinical Impact of Frequent Surveillance Imaging in the First Year Following Chemoradiation for Locally Advanced Non-small-cell Lung Cancer.

    abstract：OBJECTIVE:Uncertainty exists regarding the optimal surveillance imaging schedule following definitive chemoradiation (CRT) for locally advanced non-small-cell lung cancer (LA-NSCLC) with regards to both frequency and modality. We sought to document the clinical impact of frequent (at least every 4 months) surveillance ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2016.11.010

    authors： Ho QA,Harandi NK,Daly ME

    更新日期：2017-07-01 00:00:00

  • The emerging role of biomarkers in advanced non-small-cell lung cancer.

    abstract：:Novel therapies, particularly those that target vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR), have improved the treatment of advanced non-small-cell lung cancer (NSCLC). The search continues for biomarkers that can predict which patients are most likely to benefit from these th...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CLC.2010.n.019

    authors： Socinski MA

    更新日期：2010-05-01 00:00:00

  • Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC).

    abstract：BACKGROUND:Serum tumor markers are considered a negative prognostic factor in early-stages NSCLC but its role in advanced disease is controversial. The aim of this study is to analyze the prognostic value of tumor markers in advanced NSCLC. PATIENTS AND METHODS:Two hundred and seventy seven patients diagnosed in our i...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2011.03.019

    authors： Cedrés S,Nuñez I,Longo M,Martinez P,Checa E,Torrejón D,Felip E

    更新日期：2011-05-01 00:00:00

  • Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity.

    abstract：:Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatic dermatologic side effects. Skin rash is the dose-limiting factor for all EGFR inhibitors and is usually dose related and reversible. Microbiologic stains and cultures from skin rash usually do not show an infectious cause. We re...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/CLC.2008.n.010

    authors： Grenader T,Gipps M,Goldberg A

    更新日期：2008-01-01 00:00:00

  • Imaging features associated with disease progression after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer.

    abstract：INTRODUCTION/BACKGROUND:The aim of this study was to identify imaging-based predictors of progression in patients treated with SABR for stage I NSCLC. PATIENTS AND METHODS:Between March 2003 and December 2012, 117 patients with stage I NSCLC meeting our study criteria were treated with SABR at Stanford University. Med...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2013.12.011

    authors： Shultz DB,Trakul N,Abelson JA,Murphy JD,Maxim PG,Le QT,Loo BW Jr,Diehn M

    更新日期：2014-07-01 00:00:00

  • Cancer treatment involving oncolytic viruses.

    abstract：:Viruses capable of inducing lysis of malignant cells through their replication process are known as "oncolytic" viruses. Clinical trials in oncology have been performed with oncolytic viruses for nearly fifty years. Both systemic and intratumoral routes of administration have been explored. Toxicity has generally been...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/clc.1999.n.003

    authors： Nemunaitis JJ

    更新日期：1999-08-01 00:00:00

  • Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer.

    abstract：:Small-cell lung cancer (SCLC) is distinguished from non-small-cell lung cancer by its rapid growth and more frequent metastases. Although patients with SCLC are highly responsive to chemotherapy and radiation therapy, long-term prognosis remains poor, with relapse and disease recurrence occurring in almost all cases. ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.cllc.2016.07.004

    authors： Chae YK,Pan A,Davis AA,Mohindra N,Matsangou M,Villaflor V,Giles F

    更新日期：2017-03-01 00:00:00

  • Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.

    abstract：INTRODUCTION:The objective of this study was to present the outcomes of moderately hypofractionated helical intensity-modulated radiation therapy (HT) with/without simultaneous integrated boost (SIB) on fluorodeoxyglucose-positron emission tomography (FDG-PET) positive areas (gross tumor volume [GTV]-PET) for patients ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2018.08.019

    authors： Fodor A,Broggi S,Incerti E,Dell'Oca I,Fiorino C,Samanes Gajate AM,Pasetti M,Cattaneo MG,Passoni P,Gianolli L,Calandrino R,Picchio M,Di Muzio N

    更新日期：2019-01-01 00:00:00

  • Prognostic factors in the radical nonsurgical treatment of stage IIIB non-small-cell lung cancer.

    abstract：BACKGROUND:Many patients diagnosed with stage IIIB (AJCC sixth edition; T4, N3, or both; no pleural effusion) non-small-cell lung cancer (NSCLC) are treated with curative intent, despite a low cure rate. Guidelines are required to help select patients for radical therapy so that the patients with little chance of cure ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2013.12.007

    authors： Russell K,Healy B,Pantarotto J,Laurie SA,MacRae R,Sabri E,Wheatley-Price P

    更新日期：2014-05-01 00:00:00